GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yuyu Pharma Inc (XKRX:000220) » Definitions » Piotroski F-Score

Yuyu Pharma (XKRX:000220) Piotroski F-Score : 4 (As of May. 05, 2024)


View and export this data going back to 1975. Start your Free Trial

What is Yuyu Pharma Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Yuyu Pharma has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Yuyu Pharma's Piotroski F-Score or its related term are showing as below:

XKRX:000220' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 7
Current: 4

During the past 13 years, the highest Piotroski F-Score of Yuyu Pharma was 7. The lowest was 2. And the median was 3.


Yuyu Pharma Piotroski F-Score Historical Data

The historical data trend for Yuyu Pharma's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yuyu Pharma Piotroski F-Score Chart

Yuyu Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 3.00 3.00 2.00 4.00

Yuyu Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 1.00 2.00 2.00 4.00

Competitive Comparison of Yuyu Pharma's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Yuyu Pharma's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yuyu Pharma's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Yuyu Pharma's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Yuyu Pharma's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 96.106 + -3459.231 + -2731.213 + -1086.561 = ₩-7,181 Mil.
Cash Flow from Operations was -851.237 + -5553.151 + -2430.976 + 9256.221 = ₩421 Mil.
Revenue was 34293.848 + 34216.4 + 34090.872 + 34608.469 = ₩137,210 Mil.
Gross Profit was 13816.466 + 12542.866 + 11204.337 + 11332.939 = ₩48,897 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(195205.073 + 196576.561 + 200585.523 + 196582.95 + 198213.527) / 5 = ₩197432.7268 Mil.
Total Assets at the begining of this year (Dec22) was ₩195,205 Mil.
Long-Term Debt & Capital Lease Obligation was ₩14,021 Mil.
Total Current Assets was ₩101,597 Mil.
Total Current Liabilities was ₩49,975 Mil.
Net Income was -293.151 + -1399.576 + -2085.78 + -2209.174 = ₩-5,988 Mil.

Revenue was 35526.189 + 34474.152 + 34142.288 + 34738.428 = ₩138,881 Mil.
Gross Profit was 14014.069 + 13666.356 + 11939.314 + 13693.405 = ₩53,313 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(192985.288 + 195777.196 + 192544.305 + 189858.207 + 195205.073) / 5 = ₩193274.0138 Mil.
Total Assets at the begining of last year (Dec21) was ₩192,985 Mil.
Long-Term Debt & Capital Lease Obligation was ₩1,851 Mil.
Total Current Assets was ₩96,358 Mil.
Total Current Liabilities was ₩64,316 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Yuyu Pharma's current Net Income (TTM) was -7,181. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Yuyu Pharma's current Cash Flow from Operations (TTM) was 421. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-7180.899/195205.073
=-0.03678644

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-5987.681/192985.288
=-0.03102662

Yuyu Pharma's return on assets of this year was -0.03678644. Yuyu Pharma's return on assets of last year was -0.03102662. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Yuyu Pharma's current Net Income (TTM) was -7,181. Yuyu Pharma's current Cash Flow from Operations (TTM) was 421. ==> 421 > -7,181 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=14020.963/197432.7268
=0.07101641

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=1851.402/193274.0138
=0.00957916

Yuyu Pharma's gearing of this year was 0.07101641. Yuyu Pharma's gearing of last year was 0.00957916. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=101596.546/49975.203
=2.03293914

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=96357.746/64315.528
=1.49820345

Yuyu Pharma's current ratio of this year was 2.03293914. Yuyu Pharma's current ratio of last year was 1.49820345. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Yuyu Pharma's number of shares in issue this year was 15.951. Yuyu Pharma's number of shares in issue last year was 16.13. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=48896.608/137209.589
=0.35636436

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=53313.144/138881.057
=0.38387628

Yuyu Pharma's gross margin of this year was 0.35636436. Yuyu Pharma's gross margin of last year was 0.38387628. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=137209.589/195205.073
=0.70289971

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=138881.057/192985.288
=0.71964583

Yuyu Pharma's asset turnover of this year was 0.70289971. Yuyu Pharma's asset turnover of last year was 0.71964583. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+0+1+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Yuyu Pharma has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Yuyu Pharma  (XKRX:000220) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Yuyu Pharma Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Yuyu Pharma's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Yuyu Pharma (XKRX:000220) Business Description

Traded in Other Exchanges
Address
197, Dongho-ro, Yuyu Building, Jung-gu, Seoul, KOR
Yuyu Pharma Inc. manufactures and markets medicines. The major product is the medicines for Alzheimer's, which accounts for 45% of total revenue. The company also engages in health aid foods, rental of oxygen generator and analysis of medicines.

Yuyu Pharma (XKRX:000220) Headlines

No Headlines